Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 5, 2020

Anticancer effects of novel NSAIDs derivatives on cultured human glioblastoma cells

  • Özlem Özdemir , Lisa Marinelli , Ivana Cacciatore , Michele Ciulla , Bugrahan Emsen ORCID logo EMAIL logo , Antonio Di Stefano , Adil Mardinoglu and Hasan Turkez


Several epidemiologic, clinical and experimental reports indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) could have a potential as anticancer agents. The aim of this study was the evaluation of cytotoxic potential in human glioblastoma cells of novel synthesized NSAID derivatives, obtained by linking, through a spacer, α-lipoic acid (ALA) to anti-inflammatory drugs, such as naproxen (AL-3, 11 and 17), flurbiprofen (AL-6, 13 and 19) and ibuprofen (AL-9, 15 and 21). The effects on the level of gene expression were also determined using quantitative real-time polymerase chain reaction (qRT-PCR) analysis. According to our results, NSAID derivatives exhibited concentration dependent cytotoxic effects on U87-MG cell line when compared with the control group. Moreover, treatment of the most active compounds (AL-3, AL-6 and AL-9) caused upregulation of tumor suppressor gene PTEN and downregulation of some oncogenes such as AKT1, RAF1 and EGFR. In conclusion, our results revealed that AL-3, AL-6 and AL-9 could be suitable candidates for further investigation to develop new pharmacological strategies for the prevention of cancer.

Corresponding author: Bugrahan Emsen, Department of Biology, Kamil Özdağ Faculty of Science, Karamanoğlu Mehmetbey University, Karaman, Turkey, E-mail:

Funding source: Erzurum Technical University

Award Identifier / Grant number: 2015-12


This study was supported by Erzurum Technical University with the grant 2015-12.

  1. Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This study was supported by Erzurum Technical University with the grant 2015-12.

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.


1. Kuramoto, K, Suzuki, S, Sakaki, H, Takeda, H, Sanomachi, T, Seino, S, et al. Licochalcone a specifically induces cell death in glioma stem cells via mitochondrial dysfunction. FEBS Open Bio 2017;7:835–44. in Google Scholar

2. Anjum, K, Shagufta, BI, Abbas, SQ, Patel, S, Khan, I, Shah, SAA, et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review. Biomed Pharmacother 2017;92:681–9. in Google Scholar

3. Cobanoglu, G, Turacli, I, Ozkan, A, Ekmekci, A. Flavopiridol’s antiproliferative effects in glioblastoma multiforme. J Canc Res Therapeut 2016;12:811–7 in Google Scholar

4. Ranjan, A, Wright, S, Srivastava, SK. Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth. Oncotarget 2017;8:47632–41. in Google Scholar

5. Pereira, M. Can pomegranate prevent prostate cancer?. J Canc Res Therapeut 2007;3:166. in Google Scholar

6. Demircia, S, Dogana, A, Türkmend, NB, Telcia, D, Çaglayanc, AB, Bekerc, MC, et al. Poloxamer P85 increases anticancer activity of Schiff base against prostate cancer in vitro and in vivo. Anti Canc Drugs 2017;28:869–79. in Google Scholar

7. Rao, CV, Reddy, BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004;4:29–42. in Google Scholar

8. DuBois, RN. NSAIDs and prostate cancer risk. Cancer J 2006;12:108–9.Search in Google Scholar

9. de Groot, DJA, de Vries, EGE, Groen, HJM, de Jong, S. Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 2007;61:52–69. in Google Scholar

10. Jänne, PA, Mayer, RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960–8. in Google Scholar

11. Kirschenbaum, A, Liu, X-H, Yao, S, Levine, AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001;58:127–31. in Google Scholar

12. Amin, R, Kamitani, H, Sultana, H, Taniura, S, Islam, A, Sho, A, et al. Aspirin and indomethacin exhibit antiproliferative effects and induce apoptosis in T98G human glioblastoma cells. Neurol Res 2003;25:370–6. in Google Scholar

13. Sareddy, GR, Kesanakurti, D, Kirti, PB, Babu, PP. Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/β-Catenin/Tcf signaling pathway in human glioblastoma cells. Neurochem Res 2013;38:2313–22. in Google Scholar

14. Gomaa, AMS, Abd El-Mottaleb, NA, Aamer, HA. Antioxidant and anti-inflammatory activities of alpha lipoic acid protect against indomethacin-induced gastric ulcer in rats. Biomed Pharmacother 2018;101:188–94. in Google Scholar

15. Lin, H-Y, Han, H-W, Sun, W-X, Yang, Y-S, Tang, C-Y, Lu, G-H, et al. Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors. Eur J Med Chem 2018;144:137–50. in Google Scholar

16. Seifar, F, Khalili, M, Khaledyan, H, Amiri Moghadam, S, Izadi, A, Azimi, A, et al. α-lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: a review. Nutr Neurosci 2019;22:306–16. in Google Scholar

17. Deveci, HA, Akyuva, Y, Nur, G, Nazıroğlu, M. Alpha lipoic acid attenuates hypoxia-induced apoptosis, inflammation and mitochondrial oxidative stress via inhibition of TRPA1 channel in human glioblastoma cell line. Biomed Pharmacother 2019;111:292–304. in Google Scholar

18. Cacciatore, I, Marinelli, L, Fornasari, E, Cerasa, LS, Eusepi, P, Türkez, H, et al. Novel NSAID-derived drugs for the potential treatment of Alzheimer’s disease. Int J Mol Sci 2016;17:1035. in Google Scholar

19. Emsen, B, Aslan, A, Turkez, H, Taghizadehghalehjoughi, A, Kaya, A. The anti-cancer efficacies of diffractaic, lobaric, and usnic acid: in vitro inhibition of glioma. J Canc Res Therapeut 2018;14:941–51. in Google Scholar

20. Cacciatore, I, Fornasari, E, Marinelli, L, Eusepi, P, Ciulla, M, Ozdemir, O, et al. Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma. Eur J Pharmaceut Sci 2017;109:402–11. in Google Scholar

21. Qiu, J, Shi, Z, Jiang, J. Cyclooxygenase-2 in glioblastoma multiforme. Drug Discov Today 2017;22:148–56. in Google Scholar

22. Bartels, LE, Mattheolabakis, G, Vaeth, BM, LaComb, JF, Wang, R, Zhi, J, et al. The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1. Carcinogenesis 2015;37:420–9 in Google Scholar

23. Yi, Z, Yan, Z, Miyahara, K, Shimada, M, Tanaka, K-I, Hayashi, H, et al. Effects of nonsteroidal anti-inflammatory drugs on the self-renewal capacity of blast progenitors in hematological malignancies. Anticancer Res 2017;37:2315–22 in Google Scholar

24. Oksuz, E, Atalar, F, Tanırverdi, G, Bilir, A, Shahzadi, A, Yazici, Z. Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma. J Neuro Oncol 2016;126:271–8. in Google Scholar

25. Suthar, SK, Sharma, M. Recent developments in chimeric NSAIDs as anticancer agents: teaching an old dog a new trick. Mini Rev Med Chem 2016;16:1201–18 in Google Scholar

26. Shi, D-y, Liu, H-l, Stern, JS, Yu, P-z, Liu, S-l. Alpha-lipoic acid induces apoptosis in hepatoma cells via the PTEN/Akt pathway. FEBS Lett 2008;582:1667–71. in Google Scholar

27. Wang, C, Delcros, J-G, Cannon, L, Konate, F, Carias, H, Biggerstaff, J, et al. Defining the molecular requirements for the selective delivery of polyamine conjugates into cells containing active polyamine transporters. J Med Chem 2003;46:5129–38. in Google Scholar

28. Zhao, H-F, Wang, J, Shao, W, Wu, C-P, Chen, Z-P, To, S-ST, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Canc 2017;16:100. in Google Scholar

29. Pan, S-J, Zhan, S-K, Pei, B-G, Sun, Q-F, Bian, L-G, Sun, B-M. MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling. Int J Immunopathol Pharmacol 2012;25:871–81. in Google Scholar

30. Concetti, J, Wilson, CL. NFKB1 and cancer: friend or foe? Cells 2018;7:E133. in Google Scholar

31. Zhao, Z, Liu, Y, He, H, Chen, X, Chen, J, Lu, Y-C. Candidate genes influencing sensitivity and resistance of human glioblastoma to semustine. Brain Res Bull 2011;86:189–94. in Google Scholar

32. Ren, G, Liu, X, Mao, X, Zhang, Y, Stankiewicz, E, Hylands, L, et al. Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer. Genes Chromosom Cancer 2012;51:1014–23. in Google Scholar

33. Zhang, Z, Song, X, Tian, H, Miao, Y, Feng, X, Li, Y, et al. MicroRNA-137 inhibits growth of glioblastoma through EGFR suppression. Am J Transl Res 2017;9:1492–9.Search in Google Scholar

34. Kafka, A, Tomas, D, Beroš, V, Pećina, HI, Zeljko, M, Pećina-Šlaus, N. Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of e-cadherin. Int J Mol Sci 2014;15:10635–51. in Google Scholar

35. Holmen, SL, Williams, BO. Essential role for ras signaling in glioblastoma maintenance. Cancer Res 2005;65:8250–5. in Google Scholar

36. Behling, F, Schittenhelm, J. Oncogenic BRAF alterations and their role in brain tumors. Cancers 2019;11:794. in Google Scholar

37. Tao, T, Wang, Y, Luo, H, Yao, L, Wang, L, Wang, J, et al. Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas. Eur J Canc 2013;49:3055–63. in Google Scholar

38. Turkez, H, Tozlu, OO, Lima, TC, de Brito, AEM, de Sousa, DP. A comparative evaluation of the cytotoxic and antioxidant activity of Mentha crispa essential oil, its major constituent rotundifolone, and analogues on human glioblastoma. Oxid Med Cell Longev 2018;2018:2083923. in Google Scholar

Received: 2020-04-27
Accepted: 2020-08-22
Published Online: 2020-09-05
Published in Print: 2021-07-27

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 24.2.2024 from
Scroll to top button